Roche Notches Up First Approval For CD20xCD3 Bispecific Lunsumio
Positioned As ‘Off-The-Shelf’ Rival To CAR-Ts
Roche has gained approval for the first of its two bispecific therapies for lymphoma, but will face stiff competition from Genmab and AbbVie’s late-stage rival.
You may also be interested in...
Genmab Geared Up To Launch Epkinly With AbbVie
The Danish group, along with partner AbbVie, is all set for a commercial battle with Roche as Epkinly hits the US market for refractory diffuse large B-cell lymphoma a few weeks ahead of expected approval for the Swiss major’s same-in-class rival glofitamab.
Physicians Ponder CD20 Bispecifics’ Transition To Community As Lunsumio US Debut Approaches
Management of CRS will take getting used to, while B-cell aplasia takes on a new importance in the pandemic era, according to presentations at ASH.
Roche Can Extend Lymphoma Lead But Is Still Playing Catch-Up In Myeloma And CAR-T
Roche looks set to keep the upper hand in lymphoma with Polivy and its twin bispecific drugs, but Johnson & Johnson remains the company to beat in multiple myeloma.